Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 390 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-central Nervous System Pathology Clear all
Recruiting Not applicable Interventional

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

NCT07445074
View directory record Official record
Conditions
Epilepsy, Seizure
Interventions
Medilepsy® Chatbot AI-Enhanced, Medilepsy® Chatbot Standard
Other
Lead sponsor
University of Central Florida
Other
Eligibility
14 Years to 24 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Active, not recruiting Not applicable Interventional

CHAMPION-AF Clinical Trial

NCT04394546
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

NCT02534844
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
Parts A/B: Adrabetadex, Parts A/B: Sham Control
Drug · Other
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828
View directory record Official record
Conditions
Epilepsy With Partial On-set Seizures
Interventions
Eslicarbazepine Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Downey, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 23, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Biomarker for Seizures

NCT03441867
View directory record Official record
Conditions
Seizure Disorder, Seizure Disorder, Post Traumatic, Traumatic Brain Injury, Non-Epileptic Seizure, Conversion Disorder, Magnetic Resonance Imaging, Head Injury, Epilepsy
Interventions
Cognitive Behavioral Therapy for Seizures, Standard Medical Care
Behavioral · Other
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

NCT00991419
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[18F]AZD4694
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 23, 2026, 10:37 PM EDT
Completed No phase listed Observational

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
Exonhit
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 23, 2026, 10:37 PM EDT
Recruiting Phase 4 Interventional

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

NCT03968393
View directory record Official record
Conditions
Stroke, Atrial Fibrillation
Interventions
Non-vitamin K oral anticoagulant (NOAC)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
2,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Completed No phase listed Observational Results available

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

NCT00416312
View directory record Official record
Conditions
Lymphoma
Interventions
Patient-specific dosimetry, conventional dosimetry
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain

NCT03761277
View directory record Official record
Conditions
Chronic Non-malignant Pain, Chronic Pain, Pain, Back, Pain, Leg
Interventions
Medtronic SynchroMed™ II infusion system, Preservative-free morphine sulfate (PFMS)
Device · Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Anchorage, Alaska • Carlsbad, California • Napa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

NCT00994500
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Medulloepithelioma, Childhood Meningioma, Childhood Mixed Glioma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Oligodendroglioma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
Interventions
Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 91 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 23, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT07721025
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
LX2006, Usual Care
Genetic · Other
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

NCT02381457
View directory record Official record
Conditions
22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
20,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
16
States / cities
San Francisco, California • Camden, New Jersey • Mount Laurel, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 23, 2026, 10:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Transitioning to a Valve -Gated Intrathecal Drug Delivery System

NCT04312685
View directory record Official record
Conditions
Pain, Pain, Chronic, Pain, Intractable, Pain, Back
Interventions
Prometra II Programmable Pump system - Flowonix Medical
Device
Lead sponsor
Bux, Anjum, MD
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
Idaho Falls, Idaho • Overland Park, Kansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 23, 2026, 10:37 PM EDT
Not listed Not applicable Interventional

tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy

NCT03402854
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegic Cerebral Palsy, Spastic Hemiplegic Cerebral Palsy, Spastic Hemiparesis, Spastic Hemiplegia
Interventions
active transcranial direct current stimulation, bimanual training
Device · Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 23, 2026, 10:37 PM EDT
Completed No phase listed Observational

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

NCT01417520
View directory record Official record
Conditions
Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

NCT06510582
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Bevacizumab 2 mg/kg, Bevacizumab 4 mg/kg
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Completed No phase listed Observational

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

NCT00006342
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma
Interventions
chromosomal translocation analysis, gene rearrangement analysis, mutation analysis
Genetic
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 23, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

Apathy in Parkinson Disease TMS Study

NCT06087926
View directory record Official record
Conditions
Parkinson Disease
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
55 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00436618
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions
Everolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 10:37 PM EDT